Skip to main content
Sergio Giralt, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

SergioA.GiraltMD

Oncology New York, NY

Hematologic Oncology

Chief Adult BMT Service Memorial Sloan Kettering Cancer Center

Overview of Dr. Giralt

Dr. Sergio Giralt is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Central University of Venezuela and has been in practice 34 years. Dr. Giralt accepts several types of health insurance, listed below. He is one of 467 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He also speaks multiple languages, including Spanish. He has more than 100 publications and over 500 citings.

Education & Training

  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1989 - 1993
  • TriHealth (Good Samaritan Hospital)
    TriHealth (Good Samaritan Hospital)Residency, Internal Medicine, 1986 - 1989
  • Central University of Venezuela
    Central University of VenezuelaClass of 1983

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • NY State Medical License
    NY State Medical License 2010 - 2026
  • NJ State Medical License
    NJ State Medical License 2021 - 2025
  • CT State Medical License
    CT State Medical License 2023 - 2025
  • TX State Medical License
    TX State Medical License 1991 - 2025
  • OH State Medical License
    OH State Medical License 1989 - 1998
  • American Board of Internal Medicine Internal Medicine

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Strategies to Improve Outcomes of Autologous Hematopoietic Cell Transplant in Lymphoma  
    Parastoo B Dahi, Hillard M Lazarus, Sergio A Giralt, Craig S Sauter, Nature
  • End-of-Life Care for Older AML Patients Relapsing After Allogeneic Stem Cell Transplant at a Dedicated Cancer Center  
    Sergio A Giralt, Virginia M Klimek, Richard J Lin, Ann A Jakubowski, Esperanza B Papadopoulos, Parastoo B Dahi, Nature

Abstracts/Posters

  • Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
    Sergio A. Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Sergio A Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
    Sergio Giralt, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Approach to the Treatment of the Young, Fit Patient With Myeloma: From Diagnosis to Relapse 
    60th American Society of Hematology Annual Meeting - 12/1/2018
  • The Prognostic Calculator Easix Predicts Acute Gvhd, Non-Relapse Mortality and Overall Survival in Adult Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL Webinar
    Actinium Pharmaceuticals Announces Dr. Sergio Giralt to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B via KOL WebinarFebruary 27th, 2023
  • Actinium Announces Positive Full Data Results from the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
    Actinium Announces Positive Full Data Results from the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid LeukemiaFebruary 18th, 2023
  • Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings
    Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem MeetingsJanuary 12th, 2023
  • Join now to see all

Other Languages

  • Spanish

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    First Choice
    GHI PPO
    Great West PPO
    MVP Healthcare PPO
    ODS Network
    Oxford Health Freedom
    Oxford Health Liberty
    PacificSource Preferred PSN
    Regence Oregon - Preferred Provider Network
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment